Finally, Daudi lymphoma tumors were highly responsive to IFNα AttenukineTM indicating that anti-CD38-IFNα(att) is likely a strong therapeutic candidate for multiple types of CD38-positive lymphoid cancers. Here, IFNA2 is linked to lymphoma.